LUNDBECK, LLC

H. Lundbeck A/S announced Vyepti® (eptinezumab) met primary and secondary endpoints in SUNRISE trial, reducing monthly migraine days significantly compared to placebo. Lundbeck plans to discuss with regulatory authorities to make Vyepti available in Asia. Safety profile was similar to placebo, with COVID-19 and nasopharyngitis as most common adverse events.

Lundbeck's Vyepti® (eptinezumab) met primary and secondary endpoints in phase III SUNRISE trial, showing significant reductions in monthly migraine days and early preventive effects, with plans to discuss regulatory approval for Asian markets.

Lundbeck aims to deliver four new molecular entities in phase 3 trials by 2026, including an epilepsy drug from its $2.6 billion Longboard Pharma acquisition. Rexulti and Vyepti will drive mid-single-digit revenue growth through 2027, accounting for nearly two-thirds of Lundbeck's revenues. The pipeline includes amlenetug for multiple system atrophy, Lu AG09222 for migraine prevention, Lu AG13909 for Cushing's disease and congenital adrenal hyperplasia, and bexicaserin for rare forms of epilepsy. Lundbeck anticipates peak sales of $1.5 billion to $2 billion for bexicaserin if approved for multiple developmental and epileptic encephalopathies. The company is preparing for the loss of market exclusivity for antidepressant Trintellix/Brintellix in 2026 and targets two to three new product launches before 2030. Lundbeck will write down part of the book value of its 2018 Abide Therapeutics acquisition due to the failure of an early-stage candidate.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, gaining bexicaserin, an investigational treatment for seizures in Dravet syndrome and other DEEs. Bexicaserin, an oral therapy targeting 5-HT2C receptors, showed significant seizure reduction in Phase 1b/2a trials and maintained efficacy in a one-year extension study. The acquisition aims to address critical unmet needs in severe epilepsies.

Lundbeck agrees to buy neuroscience firm Longboard.

Bright Minds Biosciences' stock surged over 1,500% due to Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals, whose lead asset, bexicaserin, targets 5-HT2C receptors. Bright Minds' BMB-101, also a 5-HT2C agonist for DEEs, initiated its Phase 2 study last month, positioning it similarly to Longboard.

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn, aiming to bolster its neuro-rare franchise with Longboard's leading drug, bexicaserin, targeting rare epilepsies. The deal is expected to close in Q4 2024, subject to regulatory approvals and conditions.

Lundbeck acquires Longboard for $60 per share, totaling DKK 17bn ($2.5bn).

Not all 85 Longboard Pharmaceuticals employees will be part of Lundbeck’s plans to create double-digit billion-dollar revenues from Longboard’s most promising drug.